BioSpace News Archive

The companies have received all required regulatory approvals to complete the deal, the largest for the sector in the past three years and the biggest for the hot antibody-drug conjugate market.

IRLAB Therapeutics AB announced that the company has been granted a new patent in Europe related to both a new salt of the drug candidate pirepemat and the process for its preparation.

Meilleur Technologies, Inc. announced a research collaboration agreement with the Young Blood Institute on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography scans to assess the status of amyloid plaque in the brain.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the appointment of Bernd Schmidt, a senior leader with extensive experience in Chemistry, Manufacturing and Controls, as Chief Technical Officer, effective as of today.

Icosavax, Inc. announced positive topline interim results from its Phase 2 clinical trial of IVX-A12 against respiratory syncytial virus and human metapneumovirus in older adults.

ViroCell Biologics announces a new partnership with University College London to advance Professor Persis Amrolia’s innovative chimeric antigen receptor T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia.

ISA Pharmaceuticals B.V. announced positive anti-tumor response data with ISA101b, an HPV16 directed therapeutic cancer vaccine given in combination with Libtayo®, an anti-PD1 checkpoint inhibitor.

BioNxt Solutions Inc. is pleased to announce that it has received delivery of state-of-the-art coating and cutting equipment necessary for the buildout of commercial manufacturing capacity at its Vektor Pharma TF GmbH facility in Baden-Württemberg, Germany.

AstriVax is pleased to announce that it has been selected for funding by Flanders Innovation & Entrepreneurship.

Icosavax, Inc. announced it has entered into a definitive agreement pursuant to which AstraZeneca, through an acquisition subsidiary, will initiate a tender offer to acquire all of Icosavax’s outstanding shares for a price of $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones.